Combination immunotherapies comprising IL-15 superagonists
Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.
1. A composition comprising a first recombinant adenovirus subtype 5 (Ad5) vector comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding an HPV (human papilloma virus) E6 antigen, and:
a) a second recombinant adenovirus vector comprising a nucleic acid sequence encoding an IL-15N72D domain of a human interleukin-15 (IL-15) superagonist complex and an IL-15RαSu/Fc fusion domain of the IL-15 superagonist complex; or
b) a third recombinant adenovirus vector comprising a nucleic acid sequence encoding an IL-15N72D domain of a human IL-15 superagonist complex and fourth recombinant adenovirus vector comprising a nucleic acid sequence encoding an IL-15RαSu/Fc fusion domain of the IL-15 superagonist complex.
2. The composition of claim 1 , wherein the IL-15 superagonist complex is a multimeric protein complex.
3. The composition of claim 1 , wherein the IL-15 superagonist complex is ALT-803.
4. The composition of claim 1 , wherein the first recombinant adenovirus vector, the second recombinant adenovirus vector, the third recombinant adenovirus vector, and the fourth recombinant adenovirus vector comprise recombinant replication defective adenovirus vectors.
5. The composition of claim 4 , wherein the recombinant replication defective adenovirus vectors are adenovirus subtype 5 (Ad5)-based vectors.
6. The composition of claim 1 , wherein the composition comprises at least 1×10 9 viral particles in a single dose.
7. The composition of claim 1 , wherein the composition or the first recombinant adenovirus vector further comprises a nucleic acid sequences encoding a costimulatory molecule.
8. The composition of claim 1 , wherein the composition further comprises an immune pathway checkpoint modulator.
9. The composition of claim 1 , wherein the composition further comprises an anti-CEA antibody, a chemotherapeutic agent, a population of engineered natural killer (NK) cells.
10. A composition comprising a first recombinant adenovirus subtype 5 (Ad5) vector comprising:
a deletion in an E1 gene region;
a deletion in an E2b gene region;
a nucleic acid sequence encoding a human papilloma virus E6;
a nucleic acid sequence encoding an IL-15N72D domain of a human interleukin-15 (IL-15) superagonist complex; and
an IL-15RαSu/Fc fusion domain of the IL-15 superagonist complex.